Predictive Oncology (NASDAQ: POAI), together with its
subsidiary, TumorGenesis, Inc., today announced that it has selected US
Biological Corporation of Salem, Massachusetts as the manufacturer and
distributor of its innovative culture media for growing ovarian tumor cells.
TumorGenesis media are specially formulated to help researchers isolate and
maintain the unique histological and basic biological signatures of
heterogeneous ovarian cell types while growing them in the laboratory, unlike
traditional cell culture media that select for one or two fast growing cell
types. “Using these proprietary media our partners have identified 25 cell
types from ovarian tumors, which to a large degree have never been screened or
studied by researchers,” TumorGenesis, Inc. President Richard Gabriel said in
the news release. “The resulting cells have a 95+% match to cells found in
patient bodies.”
To view the full press release, visit http://ibn.fm/yje6z
About Predictive Oncology Inc.
Predictive Oncology (NASDAQ: POAI) operates through five
segments (Domestic, International, Clinical, CRO and DCHIP), which contain four
subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe.
Helomics applies artificial intelligence to its rich data gathered from patient
tumors to both personalize cancer therapies for patients and drive the
development of new targeted therapies in collaborations with pharmaceutical
companies. Helomics’ CLIA-certified lab provides clinical testing that assists
oncologists in individualizing patient treatment decisions, by providing an
evidence-based roadmap for therapy. In addition to its proprietary precision
oncology platform, Helomics offers boutique CRO services that leverage its
TruTumor(TM), patient-derived tumor models coupled to a wide range of
multi-omics assays (genomics, proteomics and biochemical), and an AI-powered
proprietary bioinformatics platform (“D- CHIP”) to provide a tailored solution
to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary
is developing a new rapid approach to growing tumors in the laboratory, which
essentially “fools” cancer cells into thinking they are still growing inside a
patient. Its proprietary Oncology Discovery Technology Platform kits will
assist researchers and clinicians to identify which cancer cells bind to
specific biomarkers. Once the biomarkers are identified they can be used in
TumorGenesis’ Oncology Capture Technology Platforms which isolate and help
categorize an individual patient’s heterogeneous tumor samples to enable the
development of patient specific treatment options. Helomics and TumorGenesis
are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division
markets its patented and FDA cleared STREAMWAY System, which automates the
collection, measurement and disposal of waste fluid, including blood,
irrigation fluid and others, within a medical facility, through both domestic
and international divisions. The company has achieved sales in five of the
seven continents through both direct sales and distributor partners. For more
information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
